SITC leaders have prioritized the following areas of focus in addressing regulatory issues relating to the field of cancer immunotherapy:
SITC has forged strategic relationships with government and regulatory entities from around the world to address key regulatory issues including formal liaison relationships with the U.S. FDA and the National Cancer Institute/National Institutes of Health.
Click here to view a complete listing of these institutions.
There is an urgent need among practicing oncologists and nurses for treatment algorithms that guide management of immunotherapy-related toxicities. Similarly, standardized templates for reporting adverse events in clinical trials are needed in order to facilitate monitoring and reporting of toxicities, an effort which is considered a high priority by the U.S. FDA.
To this end, SITC is taking the lead to convene a one-day Toxicity Management Workshop on Friday, March 31, 2017, in Washington, D.C. Click here to learn more about this event.
This may be due to an alternate immune checkpoint, CD200 (OX2) checkpoint blockade. The immuneosuppressive CD200 protein shuts down the immune system through multiple mechanisms (Xiong et al, 2016). We demonstrated that human glioblastoma in the top ...
While I agree with Stephanie's detailed account, simply put checkpoint molecules are a signature of exhausted/ chronically stimulated lymphocytes and therefore serves as a feedback mechanism to mitigate the immune activation from entering an overdrive ...
Hi Stephanie many thanks for your ample reply. It makes sense indeed in order to secure self-antigens. However, is immune system evasion by means of immune checkpoint a matter of quality or quantity? I mean is there a cutoff for "normal"CTLA4, PD1 levels ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com